Hormonal insufficiency of the hypothalamic–pituitary–adrenal (HPA) axis is a common complication in patients who have undergone pituitary surgery. Different procedures are used to assess HPA function ...

To establish whether hypothalmic-pituitary-adrenal axis suppression is possible secondary to long-term topical ophthalmic corticosteroid use in patients who have undergone penetrating keratoplasty ...

Injecting performance enhancing corticosteroid hormones for other than medical treatment is banned, and tests exist that can detect injected hormones. Injecting synacthen, which stimulates the body to ...

This leaflet answers some common questions about Synacthen Depot. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines ...

The researchers estimate that the at-home test could reduce the number of Short Synacthen Tests undertaken for diagnosing adrenal insufficiency, from 92,000 per year to just 23,000 across England. The ...

Questcor Pharmaceuticals said today it acquired rights to develop Synacthen® (tetracosactide) and Synacthen Depot in the U.S. from Novartis Pharma and parent company Novartis, in a deal that could net ...

Questcor Pharmaceuticals has acquired the rights to develop autoimmune and inflammatory disease drugs, Synacthen and Synacthen Depot, in the US from Novartis for an upfront payment of US $60 million.